MAGLi 432_product_DataBase

Bioactivity	MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC50 values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease[1].
Invitro	MAGLi 432 (10 μΜ, 25 min) displays selectivity and potency for MAGL over other serine hydrolases in mouse and human brain lysates[1].MAGLi 432 (1 μΜ, 6 h) inhibits MAGL activity and robustly enhances 2-AG levels in human NVU cells[1]. Western Blot Analysis[1] Cell Line:
In Vivo	MAGLi 432 (intraperitoneal injection, 1 mg/kg for 3 consecutive days) inhibits MAGL in the brain and reduces arachidonic acid and PGE2 levels in LPS-induced neuroinflammation, without reducing BBB permeability and inflammatory cytokine expression in the cortex[1]. Animal Model:
Name	MAGLi 432
CAS	2361575-20-2
Formula	C22H24BrClN2O2
Molar Mass	463.80
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Alicia Kemble, et al. A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature. bioRxiv 2022.05.04.490688.

PeptideDB